Oral antihyperglycemic therapy for type 2 diabetes mellitus

404Citations
Citations of this article
434Readers
Mendeley users who have this article in their library.

Abstract

DIABETES MELLITUS is A CHRONIC DISEASE that is growing in prevalence worldwide. Pharmacologic therapy is often necessary to achieve optimal glycemic control in the management of diabetes. Orally administered antihyperglycemic agents (OHAs) can be used either alone or in combination with other OHAs or insulin. The number of available OHAs has increased significantly in the last decade, which translates into more therapeutic options and complex decision-making for physicians. This review article is designed to help with these decisions. We review the mechanism of action, efficacy and side effects of the different classes of OHAs (α-glucosidase inhibitors, biguanides, insulin secretagogues, insulin sensitizers and intestinal lipase inhibitor) and discuss the current recommendations for their use.

Cite

CITATION STYLE

APA

Cheng, A. Y. Y., & Fantus, I. G. (2005, January 18). Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ. Canadian Medical Association Journal. Canadian Medical Association. https://doi.org/10.1503/cmaj.1031414

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free